Sector News

GSK opens new vaccines plant in Rockville

December 14, 2016
Life sciences

GlaxoSmithKline’s vaccines business is buoyant at the moment, and the opening of its first vaccine R&D facility in the U.S. yesterday gave the company a chance to celebrate that success.

The unit in Rockville, MD, officially opened for business yesterday, and will house 450 researchers—including 200 new hires—and be backed by $50 million in funding over the next two years. It will sit alongside Rixensart in Belgium and Siena in Italy as GSK’s three main vaccine R&D centers.

GSK said Rockville will be the base for 12 of its vaccine programs, including shingles vaccine Shingrix which was filed for approval in October and candidates for respiratory syncytial virus (RSV), group B streptococcus and dengue fever, as well as its recently-announced Zika virus project.

The company has previously highlighted Rockville as an ideal location, thanks to its close proximity to the National Institutes of Health (NIH), PATH—which is already a GSK partner for malaria vaccine development—and the thriving bioscience hub in Washington DC.

It will also take the lead on GSK’s biopreparedness model, which aims to develop new vaccines against emerging pathogens quickly and efficiently and make them available as cheaply as possible—with a “no profit/no loss” approach.

The opening underscores the importance of GSK’s vaccine business, which was swelled last year by the purchase of Novartis’ vaccine unit include meningitis B short Bexsero.

Under GSK’s management the portfolio has grown strongly, with GSK’s vaccines chief medical officer Thomas Breuer telling Bloomberg in the summer that the company expects to deliver nine times the 2016 sales levels predicted by Novartis ahead of the takeover.

Vaccines was GSK’s standout business in its third-quarter results, with 18% growth £3.45 billion in the first nine months of the year on rising demand for Bexsero and strong flu vaccine sales.

“Our investment [in Rockville] signifies our commitment to discovering and developing new vaccines across a range of pressing public health priorities, including those important here in the U.S.”, said Luc Debruyne, president of GSK Vaccines.

“We look forward to fruitful partnerships and collaborations in this community to advance the science of vaccines, and help improve health of millions of people around the world.”

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.